openPR Logo
Press release

Refractory Multiple Myeloma Pipeline Appears Promising With 75+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment | DelveInsight

07-21-2025 05:44 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Refractory Multiple Myeloma Pipeline Appears Promising With

DelveInsight's, "Refractory Multiple Myeloma Pipeline Insight 2025" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Refractory Multiple Myeloma pipeline landscape. It covers the Refractory Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Refractory Multiple Myeloma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Refractory Multiple Myeloma Pipeline Report to explore emerging therapies, key Refractory Multiple Myeloma Companies, and future Refractory Multiple Myeloma treatment landscapes @ Refractory Multiple Myeloma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/refractory-multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Refractory Multiple Myeloma Pipeline Report

* In July 2025, Sanofi announced a study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.
* In July 2025, Janssen Research & Development LLC conducted a study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, and to better characterize the signs or symptoms of talquetamab-related taste changes.
* In July 2025, Gracell Biotechnologies (Shanghai) Co., Ltd . organized a study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.Eligible subjects will be performed a leukapheresis procedure to manufacture GC012F. Subjects will receive a single dose of GC012F infusion at specified dose levels, after three consecutive days of lymphodepletion consisting of fludarabine and cyclophosphamide. Bridging therapy is allowed between leukapheresis and lymphodepletion.
* In July 2025, Regeneron Pharmaceuticals announced a study is researching an experimental drug called REGN7945 in combination with another experimental drug called linvoseltamab, (also known as REGN5458) (each individually called a "study drug" or "study drugs" when combined).
* In July 2025, Sanofi conducted a study is to measure the efficacy (Myeloma response) of subcutaneous (SC) isatuximab treatment in combination with carfilzomib and dexamethasone in adult participants with RRMM having received 1 to 3 prior lines of therapy, and to characterize the PK of isatuximab in combination with carfilzomib and dexamethasone after manual and On Body Delivery System (OBDS) administration. After confirmation of the feasibility of SC isatuximab by manual administration, patient will be randomized to 1 of the 2 delivery methods of SC isatuximab.
* In July 2025, Kite, A Gilead Company conducted a Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.
* In July 2025, AstraZeneca organized a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants with RRMM. This study will follow a modular protocol design evaluating AZD0305 as monotherapy and in combination with other anticancer agents.
* DelveInsight's Refractory Multiple Myeloma pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Refractory Multiple Myeloma treatment.
* The leading Refractory Multiple Myeloma Companies such as MorphoSys, Janssen Research & Development, LLC, Rapa Therapeutics, Novartis, AbbVie, MiNK Therapeutics, Amgen, Gracell Biopharmaceuticals, Inc., Zhejiang ACEA Pharmaceutical Co. Ltd., Allogene Therapeutics, Beijing InnoCare Pharma Tech Co., Ltd., Takeda, Novartis Pharmaceuticals and others.
* Promising Refractory Multiple Myeloma Pipleline Therapies such as Isatuximab SC-OBDS, Montelukast, Dexamethasone, Elotuzumab, Iberdomide, Selinexor, Bortezomib, Elranatamab,Carfilzomib, REGN5459 and others.

Stay ahead with the most recent pipeline outlook for Refractory Multiple Myeloma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Refractory Multiple Myeloma Treatment Drugs [https://www.delveinsight.com/sample-request/refractory-multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Refractory Multiple Myeloma Emerging Drugs Profile

* Felzartamab: MorphoSys

Felzartamab is an investigational human monoclonal antibody developed using MorphoSys' HuCAL Registered antibody technology. The antibody targets against CD38 present on the surface of multiple myeloma cells. The drug candidate uses antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) for tumor cell killing. Currently it is in Phase III stage of clinical trial evaluation to treat Refractory Multiple Myeloma.

* RAPA-201: Rapa Therapeutics

RAPA-201 It is a type of autologous cell therapy. The drug candidate is gene transference, T lymphocyte replacements and work on the same mechanism of action. Currently the drug is being evaluated in Phase II for the treatment of Refractory Multiple Myeloma.

* PHE885: Novartis

PHE885 is an autologous, fully human, BCMA-directed CAR T-cell therapy being developed by Novartis for the treatment of refractory multiple myeloma. It is administered through intravenous route. The therapeutic candidate consists of autologous T cells that are genetically modified to express chimeric antigen receptor that targets BCMA (B-cell maturation antigen). Currently it is in Phase II stage of clinical trials.

* ABBV 453: AbbVie

ABBV-453 is an investigational drug candidate being developed for the treatment of relapsed or refractory multiple myeloma. It is administered through oral route as tablet formulation. It acts by targeting B-cell lymphoma 2 (BCL-2) protein. Currently the drug is in Phase I stage of clinical trials.

The Refractory Multiple Myeloma Pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Refractory Multiple Myeloma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Refractory Multiple Myeloma treatment.
* Refractory Multiple Myeloma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Refractory Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Refractory Multiple Myeloma market.

Explore groundbreaking therapies and clinical trials in the Refractory Multiple Myeloma Pipeline. Access DelveInsight's detailed report now! @ New Refractory Multiple Myeloma Drugs [https://www.delveinsight.com/sample-request/refractory-multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Refractory Multiple Myeloma Companies

MorphoSys, Janssen Research & Development, LLC, Rapa Therapeutics, Novartis, AbbVie, MiNK Therapeutics, Amgen, Gracell Biopharmaceuticals, Inc., Zhejiang ACEA Pharmaceutical Co. Ltd., Allogene Therapeutics, Beijing InnoCare Pharma Tech Co., Ltd., Takeda, Novartis Pharmaceuticals and others.

Refractory Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical

Refractory Multiple Myeloma Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

Unveil the future of Refractory Multiple Myeloma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Refractory Multiple Myeloma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/refractory-multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Refractory Multiple Myeloma Pipeline Report

* Coverage- Global
* Refractory Multiple Myeloma Companies- MorphoSys, Janssen Research & Development, LLC, Rapa Therapeutics, Novartis, AbbVie, MiNK Therapeutics, Amgen, Gracell Biopharmaceuticals, Inc., Zhejiang ACEA Pharmaceutical Co. Ltd., Allogene Therapeutics, Beijing InnoCare Pharma Tech Co., Ltd., Takeda, Novartis Pharmaceuticals and others.
* Refractory Multiple Myeloma Pipleline Therapies- Isatuximab SC-OBDS, Montelukast, Dexamethasone, Elotuzumab, Iberdomide, Selinexor, Bortezomib, Elranatamab,Carfilzomib, REGN5459 and others.
* Refractory Multiple Myeloma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Refractory Multiple Myeloma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Refractory Multiple Myeloma Drug development? Find out in DelveInsight's exclusive Refractory Multiple Myeloma Pipeline Report-access it now! @ Refractory Multiple Myeloma Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/refractory-multiple-myeloma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Multiple Myeloma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* Comparative Analysis
* Felzartamab: MorphoSys
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* RAPA-201: Rapa Therapeutics
* Early Stage Products (Phase I )
* Comparative Analysis
* ABBV 453: AbbVie
* Inactive Products
* Refractory Multiple Myeloma Key Companies
* Refractory Multiple Myeloma Key Products
* Refractory Multiple Myeloma- Unmet Needs
* Refractory Multiple Myeloma- Market Drivers and Barriers
* Refractory Multiple Myeloma- Future Perspectives and Conclusion
* Refractory Multiple Myeloma Analyst Views
* Refractory Multiple Myeloma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=refractory-multiple-myeloma-pipeline-appears-promising-with-75-leading-biotech-and-pharma-companies-driving-innovation-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/refractory-multiple-myeloma-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Refractory Multiple Myeloma Pipeline Appears Promising With 75+ Leading Biotech and Pharma Companies Driving Innovation in the Therapeutics Segment | DelveInsight here

News-ID: 4112638 • Views:

More Releases from ABNewswire

How to Pick the Best Online Chemistry Tutoring Platform
How to Pick the Best Online Chemistry Tutoring Platform
Image: https://www.abnewswire.com/upload/2025/10/814f4b38d9855ce5fcc0509bfebaa240.jpg Choosing the right chemistry tutoring platform can make the difference between academic success and continued struggles with complex reactions and molecular structures. With students increasingly turning to digital solutions for personalized learning support, the online chemistry tutoring market has exploded with options promising everything from AI-powered progress tracking to virtual lab experiences that transform how learners approach this challenging subject. Essential Platform Features for Effective Online Chemistry Tutoring Modern chemistry tutoring
Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight
Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Chronic Myeloid Leukemia Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Chronic Myeloid Leukemia pipeline landscape. It covers the Chronic Myeloid Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Curious
Diabetic Retinopathy Pipeline Drugs Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight
Diabetic Retinopathy Pipeline Drugs Report 2025: Emerging Therapies, Clinical De …
DelveInsight's, "Diabetic Retinopathy Pipeline Insights 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by
Diabetic Macular Edema Pipeline Outlook Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight
Diabetic Macular Edema Pipeline Outlook Report 2025: Emerging Therapies, Clinica …
DelveInsight's, "Diabetic Macular Edema Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Macular Edema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our

All 5 Releases


More Releases for Myeloma

Multiple Myeloma Drugs Market Report 2024 - Multiple Myeloma Drugs Market Growth …
"The Business Research Company recently released a comprehensive report on the Global Multiple Myeloma Drugs Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. Ready to Dive into Something Exciting? Get Your Free Exclusive
Multiple Myeloma Treatment Drugs, Pipeline Insights Report 2024
DelveInsight's, "Multiple Myeloma Pipeline Insights 2024" report provides comprehensive insights about 75+ Multiple Myeloma Companies and 80+ pipeline drugs in the Multiple Myeloma pipeline landscape. It covers the Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple Myeloma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest
Refractory Multiple Myeloma Pipeline Outlook Report 2024
elveInsight's, "Refractory Multiple Myeloma Pipeline Insight, 2024," report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Refractory Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Refractory Multiple Myeloma Pipeline Report • DelveInsight's
Multiple Myeloma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Multiple Myeloma Pipeline Insights 2024" report provides comprehensive insights about 75+ Multiple Myeloma Companies and 80+ pipeline drugs in the Multiple Myeloma pipeline landscape. It covers the Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple Myeloma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from
Multiple Myeloma Market Trends, Challenges, and Opportunities
The multiple myeloma market size was valued at $19,666.74 million in 2021, and is projected to reach $53,521.76 million by 2031, registering a CAGR of 10.5% from 2022 to 2031. Market Size By 2031 USD 53.5 billion Growth Rate CAGR of 10.5% Forecast period 2021 - 2031 Report Pages 411 𝑹𝒆𝒒𝒖𝒆𝒔𝒕 𝑺𝒂𝒎𝒑𝒍𝒆 𝑪𝒐𝒑𝒚 𝒐𝒇 𝒕𝒉𝒆 𝑹𝒆𝒑𝒐𝒓𝒕 𝑯𝒆𝒓𝒆- https://www.alliedmarketresearch.com/request-sample/3725 Multiple myeloma, a type of blood cancer that originates in plasma cells, has witnessed significant advancements in treatment and
Multiple Myeloma Market - Fighting Against Myeloma: Promising Developments in Tr …
Newark, New Castle, USA: The "Multiple Myeloma Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Multiple Myeloma Market: https://www.growthplusreports.com/report/multiple-myeloma-market/8023 This latest report researches the industry structure, sales, revenue,